Video
Dr. Staskin assesses vibegron outcomes for patients with OAB dry
Author(s):
Video Player is loading.
“Vibegron for the treatment of patients with dry overactive bladder: A subgroup analysis from the EMPOWUR trial,” presented at the 2021 American Urological Association annual meeting. Staskin is a director of the Center for Male and Female Pelvic Health and associate professor of urology at Tufts University, Boston, Massachusetts.
Related Videos
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Optimizing onabotA for OAB: What are some common misconceptions?
Investigators characterize vibegron prescribing patterns for OAB
Expert outlines advantages of batteryless sacral neuromodulation device
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
Smaller size, patient control advantages of neurostimulator for OAB
Batteryless neurostimulator found efficacious at 6-month follow-up
Colin Goudelocke, MD, on 6-month data for batteryless neurostimulator
A physical therapist’s advice for men with post-prostatectomy incontinence
Related Content
